Combination of a MIP3&#945;-antigen fusion therapeutic DNA vaccine with treatments of IFN&#945; and 5-Aza-2'Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model.

Fessler, Kaitlyn; Gordy, James T; Sandhu, Avinaash K; Hui, Yinan; Kapoor, Aakanksha R; Ayeh, Samuel K; Karanika, Styliani; Karakousis, Petros C; Markham, Richard B

Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2'Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model.

Fessler, Kaitlyn; Gordy, James T; Sandhu, Avinaash K; Hui, Yinan; Kapoor, Aakanksha R; Ayeh, Samuel K; Karanika, Styliani; Karakousis, Petros C; Markham, Richard B.

Afiliação

Fessler K; Johns Hopkins Bloomberg School of Public Health.
Gordy JT; Johns Hopkins Bloomberg School of Public Health.
Sandhu AK; Johns Hopkins Bloomberg School of Public Health.
Hui Y; Johns Hopkins Bloomberg School of Public Health.
Kapoor AR; The Johns Hopkins Hospital.
Ayeh SK; The Johns Hopkins Hospital.
Karanika S; The Johns Hopkins Hospital.
Karakousis PC; The Johns Hopkins Hospital.
Markham RB; Johns Hopkins Bloomberg School of Public Health.

Res Sq ; 2023 Aug 14.

Article em En | MEDLINE | ID: mdl-37645859

Palavras-chave

5-Aza-2'-Deoxycytidine/Decitabine/Dacogen; CD11c; CD11c+ CD8+ T cell; DNA Therapeutic Cancer Vaccine; IFNα/Interferon alpha/Type I interferon; MIP3α/CCL20; Tumor microenvironment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google